JP2016522188A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522188A5
JP2016522188A5 JP2016512076A JP2016512076A JP2016522188A5 JP 2016522188 A5 JP2016522188 A5 JP 2016522188A5 JP 2016512076 A JP2016512076 A JP 2016512076A JP 2016512076 A JP2016512076 A JP 2016512076A JP 2016522188 A5 JP2016522188 A5 JP 2016522188A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
administered
conditions
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/036651 external-priority patent/WO2014179738A1/en
Publication of JP2016522188A publication Critical patent/JP2016522188A/ja
Publication of JP2016522188A5 publication Critical patent/JP2016522188A5/ja
Pending legal-status Critical Current

Links

JP2016512076A 2013-05-03 2014-05-02 癌の処置方法 Pending JP2016522188A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03
PCT/US2014/036651 WO2014179738A1 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019026073A Division JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Publications (2)

Publication Number Publication Date
JP2016522188A JP2016522188A (ja) 2016-07-28
JP2016522188A5 true JP2016522188A5 (OSRAM) 2017-06-15

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (OSRAM)
JP (2) JP2016522188A (OSRAM)
KR (1) KR102337598B1 (OSRAM)
CN (1) CN105492007A (OSRAM)
HK (1) HK1223547A1 (OSRAM)
WO (1) WO2014179738A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180353602A1 (en) * 2015-06-29 2018-12-13 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
US20190282541A1 (en) * 2016-07-20 2019-09-19 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
KR20240042244A (ko) 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099396A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
WO2008008434A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20100305167A1 (en) * 2007-11-19 2010-12-02 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC
US20110002989A1 (en) * 2008-03-07 2011-01-06 Pfizer Inc. Methods, dosage forms and kits for administering ziprasidone without food
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
CN107982270A (zh) * 2011-09-02 2018-05-04 辛达克斯制药股份有限公司 治疗乳腺癌的方法

Similar Documents

Publication Publication Date Title
NZ750754A (en) Methods of treating eosinophilic esophagitis
JP2019112416A5 (OSRAM)
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
JP2012193216A5 (OSRAM)
JP2016522188A5 (OSRAM)
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
ZA202301198B (en) Method of treating diseases
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2016520089A5 (OSRAM)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2016510326A5 (OSRAM)
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
JP2014503593A5 (OSRAM)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2015522603A5 (OSRAM)
JP2017514858A5 (OSRAM)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2016501234A5 (OSRAM)
WO2015061790A3 (en) Genetically-associated chronic obstructive pulmonary disease treatment
JP2019528267A5 (OSRAM)
JP2017061488A5 (OSRAM)
WO2016122289A3 (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
JP2015535256A5 (OSRAM)
JP2016514142A5 (OSRAM)